SynthesisDiagnostic pathology2014
The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis.
Synthesis in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association betweenAging · 2021Pooled it
- CTLA-4 rs231775 and risk of acute renal graft rejection: an updated meta-analysis with trial sequential analysis.Scientific reports · 2020Pooled it
- The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis.PloS one · 2016Pooled it
- Donor-recipient HLA molecular mismatch and T follicular helper-related genetic variants are associated with dnDSA development after kidney transplantation.Frontiers in immunology · 2026Article
- Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis.Rheumatology (Oxford, England) · 2024Article
- Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance inWorld journal of clinical cases · 2023Article
- Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.Cancer immunology, immunotherapy : CII · 2021Article
- Impact of cytotoxic T-lymphocyte-associated protein 4 codon 17 variant and expression on vitiligo risk.Journal of clinical laboratory analysis · 2021Article
- The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell Transplantation.International journal of molecular sciences · 2021Review
- Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response.International journal of molecular sciences · 2020Review
- CD28, CTLA-4 and CCL5 gene polymorphisms in patients with rheumatoid arthritis.Clinical rheumatology · 2017Article
- Adverse Events in Cancer Immunotherapy.Advances in experimental medicine and biology · 2017Review
- A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis.International cancer conference journal · 2016Article
- Role and mechanism of vascular cell adhesion molecule-1 in the development of rheumatoid arthritis.Experimental and therapeutic medicine · 2015Article
- Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Review
- Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, a number of studies have been performed to explore the association between CTLA-4 A49G polymorphism and rheumatoid arthritis (RA). However, the results of previous works are still controversial and ambiguous.
methodsIn this work, we attempted to perform an updated meta-analysis of available case-control study in order to assess the association between CTLA-4 A49G polymorphism and RA risk. We searched the various citation databases without limits on languages. Article searching was performed by screening the references of retrieved studies manually. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the strength of the association.
resultsWe totally compiled 27 studies in 24 articles (9805 RA patients and 10691 control subjects) into our meta-analysis work. We found significant association between CTL-A4 A49G polymorphism and RA risk (GG vs. AA: OR = 1.13, 95% CI = 1.03-1.23; GA vs. AA: OR = 1.19, 95% CI = 1.07-1.33; GA + GG vs. AA: OR = 1.18, 95% CI = 1.07-1.29). In the subgroup analysis by ethnicity, evidences of significantly increased risk was also found in both Asian (GG vs. AA: OR = 1.34, 95% CI = 1.15-1.55; GA + GG vs. AA: OR = 1.24, 95% CI = 1.08-1.41) and Caucasian population (GA vs. AA: OR = 1.19, 95% CI = 1.03-1.37; GA + GG vs. AA: OR = 1.14, 95% CI = 1.01-1.29). No evidence of publication bias was found in this work.
conclusionsOur meta-analysis suggests that CTLA-4 A49G polymorphism was associated with RA risk. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_157.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.